American Diabetes Association, June 7-11

The American Diabetes Association 79th Scientific Sessions The annual meeting of the American Diabetes Association was held from June 7 to 11 in San Francisco and attracted approximately 14,000 participants […]

The American Diabetes Association 79th Scientific Sessions

The annual meeting of the American Diabetes Association was held from June 7 to 11 in San Francisco and attracted approximately 14,000 participants from around the world, including clinicians, academicians, allied health professionals, and others interested in diabetes. The conference highlighted the latest advances in diabetes research and improving patient care, with presentations focusing on treatment recommendations and advances toward a cure for diabetes.

In the PIONEER 6 trial, John Buse, M.D., Ph.D., of the University of North Carolina School of Medicine in Chapel Hill, and colleagues found that oral semaglutide was effective in lowering glucose levels and reducing the risk for major cardiovascular events in patients with type 2 diabetes and an elevated cardiovascular risk.

The investigators randomly assigned 3,183 patients with type 2 diabetes and high cardiovascular risk to receive either a 14-mg dose of semaglutide once daily (1,591 participants) or placebo (1,592 participants). After a median follow-up of 15.9 months, the investigators found that oral semaglutide reduced cardiovascular death and all-cause mortality by almost 50 percent.

“The key findings from the PIONEER program are that oral semaglutide is very effective in glucose lowering without intrinsically increasing the risk of hypoglycemia and also promotes weight loss. The cardiovascular safety trial suggests potential cardiovascular benefits, including benefits on mortality. This is all quite exciting,” Buse said. “As it suggests, an oral form of the glucagon-like peptide-1 receptor agonist class has similar benefits to the injectable form of the drug. Hopefully, this will reduce barriers to the use of this very effective class of medications.”

The PIONEER 6 trial was sponsored by Novo Nordisk, the manufacturer of semaglutide.

Press Release

In the international PREVIEW intervention study in patients at risk for developing type 2 diabetes, Ian Macdonald, Ph.D., of the University of Nottingham in the United Kingdom, and colleagues found that the combination of an initial 8 percent weight loss plus a structured lifestyle intervention with a clearly defined diet and physical activity program, delivered with a well-structured behavioral change program, was associated with an incidence of type 2 diabetes of less than one-half to one-fourth of the predicted incidence for such patients.

1 | 2 | 3
Page 1 of 3
Next »